Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Xianzhong Cheng
Observed names:
X Cheng,
X. Cheng
Institutions:
Jiangsu Cancer Hospital,
Nanjing Medical University
Observed institutions:
Wannan Medical College,
University of Oxford,
Jiangsu Cancer Hospital,
Huazhong University of Science and Technology,
Nanjing Medical University
ORCID:
0000-0003-3513-4626
Observed ORCID:
0000-0003-3513-4626
OpenAlex ID:
A5058791327
Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer
2016
·
S R Rao
, A E Snaith
, et al.
·
British Journal of Cancer
·
191
PDF
Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China
2022
·
Jing Ni
, Wenwen Guo
, et al.
·
Frontiers in Oncology
·
31
Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China
2019
·
Jing Ni
, Xianzhong Cheng
, et al.
·
Journal of Ovarian Research
·
30
PDF
Pathogenic Heteroplasmic Somatic Mitochondrial DNA Mutation Confers Platinum-Resistance and Recurrence of High-Grade Serous Ovarian Cancer
2020
·
Jing Ni
, Yan Wang
, et al.
·
Cancer Management and Research
·
21
PDF
High Serpin Family A Member 10 Expression Confers Platinum Sensitivity and Is Associated With Survival Benefit in High-Grade Serous Ovarian Cancer: Based on Quantitative Proteomic Analysis
2021
·
Wenwen Guo
, Xue He
, et al.
·
Frontiers in Oncology
·
17
Anlotinib as Exploratory Therapy for Platinum-Resistant Ovarian Cancer: A Retrospective Study on Efficacy and Safety
2020
·
Jing Ni
, Xianzhong Cheng
, et al.
·
OncoTargets and Therapy
·
16
PDF
The efficacy and safety of niraparib for ovarian cancer: a single-center observational study from China
2021
·
Jing Ni
, Xianzhong Cheng
, et al.
·
Journal of Ovarian Research
·
11
PDF
Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
2020
·
Jing Ni
, Rui Zhou
, et al.
·
Journal of Ovarian Research
·
11
PDF
Case Report: Extragonadal Yolk Sac Tumors Originating From the Endometrium and the Broad Ligament: A Case Series and Literature Review
2021
·
Xianzhong Cheng
, Qian Zhao
, et al.
·
Frontiers in Oncology
·
10
PDF
Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor
2021
·
Jing Ni
, Xianzhong Cheng
, et al.
·
Frontiers in Oncology
·
9
TCGA molecular subtypes in endometriosis-associated ovarian cancer: a systematic review and meta-analysis
2025
·
Luxin Ye
, Jiahui Chen
, et al.
·
Annals of Medicine
·
6
PDF
Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report
2022
·
Qian Zhao
, Jing Ni
, et al.
·
Reproductive Sciences
·
4
The value of secondary neoadjuvant chemotherapy in platinum-sensitive recurrent ovarian cancer: a case-control study post GOG-0213 trial
2020
·
Hongyuan Gu
, Rui Zhou
, et al.
·
Journal of Ovarian Research
·
2
PDF
Prognostic Factors and Role of Pelvic Lymphadenectomy in Patients with Uterine Sarcoma: A Multi-Center Population-Based Cohort Study
2025
·
Yunmei Zhuo
, Wanwan Ji
, et al.
·
International Journal of Women s Health
·
1
Real-world experience and prognostic factors in ovarian carcinosarcoma: a single-center retrospective study from China
2025
·
Wanwan Ji
, Yunmei Zhuo
, et al.
·
Frontiers in Oncology
·
1
PDF
Homologous recombination deficiency associated with response to poly (ADP-ribose) polymerase inhibitors in ovarian cancer patients: The first real-word data from China.
2021
·
Xiaoxiang Chen
, Jing Ni
, et al.
·
Journal of Clinical Oncology
·
1
Proteomic Profiling of Endometriosis and Ovarian Endometrioid Carcinoma: A Preliminary Exploratory Study
2026
·
Qi Xue
, Xianzhong Cheng
, et al.
·
Technology in Cancer Research & Treatment
Efficacy and Safety of Multivisceral Resection for Ovarian Cancer: A Comparative Study of Gynecologic Oncologists and Multidisciplinary Surgeons
2026
·
Luxin Ye
, Qi Xue
, et al.
·
Cancer Medicine
Exploring the optimal cutoff point and genomic characteristics for PARP inhibitor maintenance therapy in early recurrence of ovarian cancer
2026
·
Luxin Ye
, Yourong Chen
, et al.
·
Journal of Ovarian Research
Infective endocarditis after splenectomy for ovarian cancer: a case report
2025
·
Luxin Ye
, Xuening Wang
, et al.
·
BMC Surgery
Niraparib combined with anlotinib after PARPi resistance in ovarian cancer: A single-center retrospective study from China
2025
·
Xianzhong Cheng
, Ping Liu
, et al.
·
European Journal of Obstetrics & Gynecology and Reproductive Biology
[Genetic screening for a pedigree of familial hypercholesterolemia].
2022
·
F Zhu
, Y C Zhong
, et al.
·
PubMed
Adverse events as a potential clinical marker of antitumor efficacy in ovarian cancer patients treated with poly ADP-ribose polymerase (PARP) inhibitor
2021
·
Jing Ni
, Xiaoxiang Chen
, et al.
·
Gynecologic Oncology
Variance of HRD score from primary to recurrent in high-grade serous ovarian cancer.
2021
·
Xiaoxiang Chen
, Jing Ni
, et al.
·
Journal of Clinical Oncology
The Effect of Maternal Age at First Pregnancy on the Risk of Gynaecological Cancers – A Literature Review and Retrospective Analysis
2020
·
Nitish Beharee
, Zujun Shi
, et al.
·
Advances in Biochemistry and Biotechnology
Show more works
View as search
Works count:
27
Citation count:
362
H-index:
9
I10-index:
9
Year
Topic
Type